Adducin polymorphisms and the treatment of hypertension

Paolo Manunta, Lorena Citterio, Chiara Lanzani, Mara Ferrandi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in humans and animals provide very strong evidence of a causal link between high salt intake and high blood pressure. One of the candidate genes for salt-sensitive hypertension is adducin. Adducin is a heterodimeric cytoskeleton protein, the three subunits of which are encoded by genes (ADD1, ADD2 and ADD3) that map to three different chromosomes. A long series of parallel studies in the Milan hypertensive rat strain model of hypertension and humans indicated that an altered adducin function might cause hypertension through enhanced constitutive tubular sodium reabsorption. An example of a prospective efficacy of pharmacogenetics and pharmacogenomics is the detection and impact of adducin polymorphisms on hypertension. In particular, the selective advantages of diuretics in preventing myocardial infarction and stroke over other antihypertensive therapies that produce a similar blood pressure reduction in carriers of the mutated adducin may support new strategies aimed at optimizing the use of new antihypertensive agents for the prevention of hypertension-associated organ damage.

Original languageEnglish
Pages (from-to)465-472
Number of pages8
JournalPharmacogenomics
Volume8
Issue number5
DOIs
Publication statusPublished - May 2007

Fingerprint

Hypertension
Pharmacogenetics
Antihypertensive Agents
Salts
Genetic Engineering
Protein Subunits
Genetic Predisposition to Disease
adducin
Cytoskeleton
Diuretics
Genes
Public Health
Chromosomes
Sodium
Stroke
Myocardial Infarction
Blood Pressure
Therapeutics

Keywords

  • Blood pressure
  • Digitalis-like factor
  • Genetic
  • Na pump
  • Renal

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Adducin polymorphisms and the treatment of hypertension. / Manunta, Paolo; Citterio, Lorena; Lanzani, Chiara; Ferrandi, Mara.

In: Pharmacogenomics, Vol. 8, No. 5, 05.2007, p. 465-472.

Research output: Contribution to journalArticle

Manunta, Paolo ; Citterio, Lorena ; Lanzani, Chiara ; Ferrandi, Mara. / Adducin polymorphisms and the treatment of hypertension. In: Pharmacogenomics. 2007 ; Vol. 8, No. 5. pp. 465-472.
@article{150b40ad85764ca2a153a3d518c7da27,
title = "Adducin polymorphisms and the treatment of hypertension",
abstract = "Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in humans and animals provide very strong evidence of a causal link between high salt intake and high blood pressure. One of the candidate genes for salt-sensitive hypertension is adducin. Adducin is a heterodimeric cytoskeleton protein, the three subunits of which are encoded by genes (ADD1, ADD2 and ADD3) that map to three different chromosomes. A long series of parallel studies in the Milan hypertensive rat strain model of hypertension and humans indicated that an altered adducin function might cause hypertension through enhanced constitutive tubular sodium reabsorption. An example of a prospective efficacy of pharmacogenetics and pharmacogenomics is the detection and impact of adducin polymorphisms on hypertension. In particular, the selective advantages of diuretics in preventing myocardial infarction and stroke over other antihypertensive therapies that produce a similar blood pressure reduction in carriers of the mutated adducin may support new strategies aimed at optimizing the use of new antihypertensive agents for the prevention of hypertension-associated organ damage.",
keywords = "Blood pressure, Digitalis-like factor, Genetic, Na pump, Renal",
author = "Paolo Manunta and Lorena Citterio and Chiara Lanzani and Mara Ferrandi",
year = "2007",
month = "5",
doi = "10.2217/14622416.8.5.465",
language = "English",
volume = "8",
pages = "465--472",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Adducin polymorphisms and the treatment of hypertension

AU - Manunta, Paolo

AU - Citterio, Lorena

AU - Lanzani, Chiara

AU - Ferrandi, Mara

PY - 2007/5

Y1 - 2007/5

N2 - Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in humans and animals provide very strong evidence of a causal link between high salt intake and high blood pressure. One of the candidate genes for salt-sensitive hypertension is adducin. Adducin is a heterodimeric cytoskeleton protein, the three subunits of which are encoded by genes (ADD1, ADD2 and ADD3) that map to three different chromosomes. A long series of parallel studies in the Milan hypertensive rat strain model of hypertension and humans indicated that an altered adducin function might cause hypertension through enhanced constitutive tubular sodium reabsorption. An example of a prospective efficacy of pharmacogenetics and pharmacogenomics is the detection and impact of adducin polymorphisms on hypertension. In particular, the selective advantages of diuretics in preventing myocardial infarction and stroke over other antihypertensive therapies that produce a similar blood pressure reduction in carriers of the mutated adducin may support new strategies aimed at optimizing the use of new antihypertensive agents for the prevention of hypertension-associated organ damage.

AB - Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in humans and animals provide very strong evidence of a causal link between high salt intake and high blood pressure. One of the candidate genes for salt-sensitive hypertension is adducin. Adducin is a heterodimeric cytoskeleton protein, the three subunits of which are encoded by genes (ADD1, ADD2 and ADD3) that map to three different chromosomes. A long series of parallel studies in the Milan hypertensive rat strain model of hypertension and humans indicated that an altered adducin function might cause hypertension through enhanced constitutive tubular sodium reabsorption. An example of a prospective efficacy of pharmacogenetics and pharmacogenomics is the detection and impact of adducin polymorphisms on hypertension. In particular, the selective advantages of diuretics in preventing myocardial infarction and stroke over other antihypertensive therapies that produce a similar blood pressure reduction in carriers of the mutated adducin may support new strategies aimed at optimizing the use of new antihypertensive agents for the prevention of hypertension-associated organ damage.

KW - Blood pressure

KW - Digitalis-like factor

KW - Genetic

KW - Na pump

KW - Renal

UR - http://www.scopus.com/inward/record.url?scp=34248569586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248569586&partnerID=8YFLogxK

U2 - 10.2217/14622416.8.5.465

DO - 10.2217/14622416.8.5.465

M3 - Article

C2 - 17465710

AN - SCOPUS:34248569586

VL - 8

SP - 465

EP - 472

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 5

ER -